Women with operable early-stage breast cancer were enrolled in a multicenter study of neoadjuvant therapy for four 21-day cycles with capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) if human epidermal growth factor receptor 2 (HER2)-negative, and additionally, a standard trastuzumab dose if HER2-positive.
We then evaluated the clinicopathological significance of ERCC1 in early stage breast cancer (BC) (mRNA expression (<i>n</i> = 4640) and protein level, <i>n</i> = 1650 (test set), and <i>n</i> = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (<i>n</i> = 2340) and validation (TOP clinical trial cohort, <i>n</i> = 120); and protein level (<i>n</i> = 120)).
We then evaluated the clinicopathological significance of ERCC1 in early stage breast cancer (BC) (mRNA expression (<i>n</i> = 4640) and protein level, <i>n</i> = 1650 (test set), and <i>n</i> = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (<i>n</i> = 2340) and validation (TOP clinical trial cohort, <i>n</i> = 120); and protein level (<i>n</i> = 120)).
We then evaluated the clinicopathological significance of ERCC1 in early stage breast cancer (BC) (mRNA expression (<i>n</i> = 4640) and protein level, <i>n</i> = 1650 (test set), and <i>n</i> = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (<i>n</i> = 2340) and validation (TOP clinical trial cohort, <i>n</i> = 120); and protein level (<i>n</i> = 120)).
We propose a therapy for early stage breast cancer consisting of Endostatin at or above Down syndrome levels starting at least one day before surgery and continuing at that level.
We performed an economic evaluation to assess the cost-effectiveness and budget impact of adjuvant trastuzumab therapy for HER2-positive EBC in the Philippines, using healthcare system and societal perspectives, in aid of guiding coverage decisions.
We investigated the cost effectiveness of using the RS assay versus current clinical practice (CCP) in post-menopausal women with estrogen- or progesterone-receptor-positive, one to three positive axillary lymph-node ESBC from the perspective of the Canadian public healthcare system.
We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer.
We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer.
We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer.
We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer.
We have previously shown that Bcl-2 overexpression was associated with an increased risk of local recurrence in patients with early stage breast cancer.
We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC).
We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC).
We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC).
We evaluated the prognostic significance of KLK10 exon 3 methylation in patients with early-stage breast cancer since it has been shown to have a significant impact on biological characteristics of breast tumors.
We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario.
We conclude that increased expression of AIB1-YAP co-activated targets coupled with a loss of normal ANCO1 repression is critical to patterns of gene expression that mediate malignant progression of early-stage breast cancer.
We conclude that increased expression of AIB1-YAP co-activated targets coupled with a loss of normal ANCO1 repression is critical to patterns of gene expression that mediate malignant progression of early-stage breast cancer.
We conclude that increased expression of AIB1-YAP co-activated targets coupled with a loss of normal ANCO1 repression is critical to patterns of gene expression that mediate malignant progression of early-stage breast cancer.